Ran BP-M Inhibitors
The chemical class of Ran BP-M Inhibitors encompasses a broad range of compounds that indirectly modulate the activity of Ran BP-M, a protein involved in numerous cellular processes such as signal transduction and cell cycle regulation. These inhibitors operate not by directly interacting with Ran BP-M, but rather by impacting various upstream pathways that ultimately influence the protein's function. The diversity of this class reflects the complexity of cellular signaling networks, with each inhibitor possessing unique mechanisms of action. Some, like LY294002, target key signaling molecules such as mTOR and PI3K, respectively. Their inhibition results in altered cellular states, which can lead to decreased Ran BP-M activity. Inhibitors of the p38 MAPK and JNK pathways, represented by SB203580 and SP600125, respectively, demonstrate the interconnected nature of these signaling routes and their collective impact on Ran BP-M.
Additionally, the class includes compounds like Bortezomib, a proteasome inhibitor, which affects protein degradation pathways, thus indirectly influencing Ran BP-M activity. Kinase inhibitors such as Sorafenib, Sunitinib, Dasatinib, and Imatinib target various kinases involved in critical cellular signaling processes. Their broad-spectrum action on these kinases demonstrates the complex interplay of different signaling cascades and their influence on Ran BP-M. The indirect inhibition of Ran BP-M by these compounds highlights the multifaceted nature of cellular regulation and the nuanced interconnections between different signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K, which is involved in various signaling pathways, including those related to cell survival and growth. By inhibiting PI3K, LY294002 can indirectly affect Ran BP-M activity through these pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, affecting cell growth and survival pathways. By modulating these pathways, Wortmannin can indirectly influence Ran BP-M activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By influencing the p38 MAPK pathway, it could indirectly affect Ran BP-M activity, as p38 MAPK is involved in various cellular processes. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK. By affecting the JNK signaling pathway, it could indirectly impact Ran BP-M activity, as JNK is involved in several cellular processes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, can affect multiple cellular pathways including those related to protein degradation. Its impact on protein turnover could indirectly influence Ran BP-M activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases involved in cell signaling and can indirectly affect pathways related to Ran BP-M, potentially leading to its inhibition. | ||||||
Sunitinib Malate | 341031-54-7 | sc-220177 sc-220177A sc-220177B | 10 mg 100 mg 3 g | $197.00 $520.00 $1093.00 | 4 | |
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor, affecting various signaling pathways. Its action on these pathways could indirectly modulate Ran BP-M activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib, a tyrosine kinase inhibitor, can modulate various cellular signaling pathways. By influencing these pathways, Dasatinib could indirectly impact Ran BP-M activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits specific tyrosine kinases and affects several signaling pathways. Its influence on these pathways can indirectly modulate Ran BP-M activity. | ||||||